PTC Therapeutics Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 967
Employees
  • Stock Symbol
  • PTCT
Stock Symbol
  • Investments
  • 6
  • Share Price
  • $37.37
  • (As of Monday Closing)

PTC Therapeutics General Information

Description

PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Contact Information

Website
www.ptcbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 100 Corporate Court
  • South Plainfield, NJ 07080
  • United States
+1 (908) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

PTC Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$37.37 $38.09 $35.69 - $70.82 $2.69B 70.6M 437K -$5.59

PTC Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 2,526,746 3,437,771 2,564,636 1,633,131
Revenue 471,888 380,766 306,980 264,734
EBITDA (215,359) (261,708) (195,255) (89,469)
Net Income (391,058) (438,160) (251,576) (128,081)
Total Assets 2,058,669 2,208,278 1,623,782 1,119,222
Total Debt 536,430 420,438 328,030 153,014
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PTC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PTC Therapeutics‘s full profile, request access.

Request a free trial

PTC Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization
Drug Discovery
South Plainfield, NJ
967 As of 2020
00000
00000000000 00000

0000000

amco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volu
000000000000000
Cambridge, MA
000 As of 0000
00000
00000000000 00000

00 00000

nderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
000000000000000
Cambridge, MA
00 As of 0000
00000
0.000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PTC Therapeutics Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dicerna Pharmaceuticals Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
00 000000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
000000 Formerly PE-Backed Princeton, NJ 000 00000 000000&0 00000
00000000 000000000 Formerly Accelerator/Incubator backed San Diego, CA 000 000.00 000000000 000.00
000000 00000000 Formerly VC-backed Boulder, CO 000 00000 000000 - 000 00000
You’re viewing 5 of 63 competitors. Get the full list »

PTC Therapeutics Patents

PTC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020222881-A1 Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia Pending 13-Feb-2019 0000000000
AU-2020209767-A1 Method for treating an acute myeloid leukemia Pending 15-Jan-2019 000000000
CA-3126163-A1 Method for treating an acute myeloid leukemia Pending 15-Jan-2019 000000000
US-20210276937-A1 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders Pending 17-Oct-2018 000000000
AU-2019362010-A1 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders Pending 17-Oct-2018 C07C50/04

PTC Therapeutics Executive Team (28)

Name Title Board Seat Contact Info
Stuart Peltz Ph.D Chief Executive Officer, Board Member & Founder
Emily Hill Chief Financial Officer, Finance
Christine Utter Chief Accounting Officer, Head of People Services & Senior Vice President
Mark Boulding JD Executive Vice President & Chief Legal Officer, Legal
Mark Pykett Ph.D Chief Scientific Officer
You’re viewing 5 of 28 executive team members. Get the full list »

PTC Therapeutics Board Members (18)

Name Representing Role Since
Allan Jacobson Ph.D Self Founder & Board Member 000 0000
David Southwell Self Board Member 000 0000
Dawn Svoronos Self Board Member 000 0000
Emma Reeve Self Board Member 000 0000
Glenn Steele Jr. PTC Therapeutics Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

PTC Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PTC Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PTC Therapeutics‘s full profile, request access.

Request a free trial

PTC Therapeutics Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 29-May-2020 000000000000000000 00000 Biotechnology 000000 00000 00.0
00000000000 000000 29-Oct-2019 000000000 00000 00 Buildings and Property
00000000000 000000 25-Oct-2019 000000000000000000 00000 Biotechnology
0000000000 00000 17-May-2019 0000 00.000 Surgical Devices 000000 00000
Agilis Biotherapeutics 23-Aug-2018 Merger/Acquisition 00000 Biotechnology 000000 00000 00.0
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

PTC Therapeutics Subsidiaries (1)

Company Name Industry Location Founded
00000 000000000000 Biotechnology Wellesley, MA 0000
To view PTC Therapeutics’s complete subsidiaries history, request access »